Academic
Publications
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers,10.1007/s10549-007-9600-1,Breast Cancer Research and Treatment,T. By

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers   (Citations: 30)
BibTex | RIS | RefWorks Download
Purpose  There have been no studies to date which look at the relative effectiveness of different regimens of chemotherapy in women who have breast cancer and who carry a BRCA1 germ-line mutation. We wished to compare rates of response to neo-adjuvant chemotherapy in BRCA1 mutation carriers and non-carrier controls. Experimental design  From a registry of 3,479 patients, we identified 44 Polish women who carried a BRCA1 founder mutation and who had been treated with neo-adjuvant chemotherapy for breast cancer, and 41 age- and hospital-matched controls. Results  35 of the 44 BRCA1 mutation carriers (80%) experienced a partial or complete response to neo-adjuvant chemotherapy, compared to 39 of the 41 (95%) non-carriers (P = 0.05). In the hereditary subgroup, response rates differed depending on whether or not a taxane (docetaxel) was given. Six of the 15 BRCA1 carrier women given docetaxel with doxorubicin responded (complete or partial), compared to 29 of 29 given other (DNA-damaging) therapies (P = 0.001). Among the non-carriers, the rates of response to the two categories of chemotherapy were similar. Conclusions  Breast cancers among BRCA1 carriers frequently do not exhibit sensitivity to docetaxel in the neo-adjuvant setting. It is likely that normal BRCA1 is required for clinical response to mitotic spindle poisons.
Journal: Breast Cancer Research and Treatment - BREAST CANCER RES TREAT , vol. 108, no. 2, pp. 289-296, 2008
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: